Skip to main content
PepStack
Wiki · Profile

Ipamorelin

NNC 26-0161

GH SecretagoguePhase II
From$3.50/mgCompare prices
MW
711.9g/mol
Formula
C38H49N9O5

Ipamorelin is a synthetic peptide classified as a growth hormone secretagogue, derived from the structure of ghrelin, a hormone that stimulates growth hormone release. Researchers primarily study ipamorelin for its potential role in enhancing muscle growth, improving body composition, and promoting tissue regeneration. Key findings from preclinical studies suggest that ipamorelin can increase bone mineral content and stimulate the signaling pathways associated with muscle repair and growth. Additionally, studies indicate that when combined with other peptides, such as CJC-1295, ipamorelin may enhance muscle recovery in animal models. Despite these promising results, current research is limited, with a notable lack of clinical trials in humans, highlighting the need for further investigation into its safety and efficacy.

Chemical Profile

Chemical Profile

Chemical structure
Chemical Structure
FormulaC38H49N9O5
Molecular Weight711.9 g/mol
CAS Number170851-70-4
PubChem CID9831659

Half-Life

SCSubcutaneous

~2 hours

INIntranasal

Not applicable

POOral

Poor bioavailability

Ipamorelin's pharmacokinetics are characterized by a short half-life and limited oral bioavailability, necessitating injectable administration for effective use.

Mechanism

Mechanism of Action

Ipamorelin acts as a selective growth hormone secretagogue by binding to the growth hormone secretagogue receptor (GHS-R), leading to the activation of the GH/IGF-1 signaling pathway. This interaction stimulates the release of growth hormone (GH) from the anterior pituitary, which subsequently activates the insulin-like growth factor 1 (IGF-1) signaling pathway, promoting processes such as tissue regeneration, muscle growth, and bone mineralization. While the precise molecular mechanisms remain to be fully elucidated, ipamorelin is known to influence pathways involved in cellular growth and metabolism, including the mTOR and PI3K/Akt pathways.

Research

35 Research Publications

925

Total Citations

10

Human/RCT

2.1

Avg. Influence

2020

Latest

Sort
Filter
#01

Ipamorelin, the first selective growth hormone secretagogue.

AnimalInfluence6.0
97
Researchers observed that ipamorelin is a selective growth hormone secretagogue with high potency for stimulating growth hormone release without affecting other hormone levels.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#02

Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry.

In VitroInfluence1.0
86
Researchers observed that a liquid chromatography-mass spectrometry method effectively detects growth hormone releasing peptides, including ipamorelin, in human urine for doping control.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#03

Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

AnimalInfluence2.0
85
The study demonstrated that ipamorelin increased body fat and weight in both GH-deficient and GH-intact mice, suggesting GH-independent mechanisms of action.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#04

Pharmacological characterisation of a new oral GH secretagogue, NN703.

AnimalInfluence5.0
63
The study demonstrated that NN703, derived from ipamorelin, effectively stimulates growth hormone release in swine and dogs, exhibiting high potency and oral bioavailability.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#05

Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry.

In VitroInfluence1.0
59
The study demonstrated a validated screening assay for prohibited peptides, including ipamorelin, in urine, achieving high specificity and sensitivity for doping control.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#06

Seabream ghrelin: cDNA cloning, genomic organization and promoter studies.

In VitroInfluence1.0
59
Researchers observed that growth hormone expression in seabream is regulated by ipamorelin, with the ghrelin gene exhibiting tissue-specific promoter activity.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#07

Metabolism of growth hormone releasing peptides.

Animal
50
Researchers observed the identification of 28 metabolites from growth hormone releasing peptides, including ipamorelin, in urine samples from rats, which may aid in doping control analysis.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#08

Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

In VitroInfluence1.0
42
Researchers observed that ipamorelin and other GHRPs were metabolized and excreted in urine, with varying detection windows depending on individual metabolism and administration route.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#09

A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography.

In Vitro
37
Researchers observed successful detection of multiple growth hormone releasing peptides, including ipamorelin, in equine and human urine using a novel extraction and derivatization method.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#10

Novel orally active growth hormone secretagogues.

In Vitro
37
Researchers observed that a novel class of growth hormone secretagogues derived from ipamorelin exhibited oral bioavailability and maintained in vivo potency in swine.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
Safety

Safety & Handling

Research Gaps

No randomized controlled human trials have been conducted specifically on ipamorelin and its effects on musculoskeletal injuries or athletic performance. Additionally, the long-term safety and efficacy of ipamorelin in various populations, particularly in hypogonadal males and athletes, remain largely unknown, as does the detailed mechanism of action in human subjects.

Solubility

Ipamorelin is soluble in water and DMSO.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA for clinical use. Not scheduled by the DEA.

🇦🇺AU

Not approved by the TGA for therapeutic use.

🇬🇧UK

Not approved by the MHRA for medicinal use.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

41 total
5
98
3
99
1
00
4
01
2
02
1
03
2
04
1
06
2
09
1
11
2
12
1
13
2
14
1
15
2
16
2
17
4
18
1
20
2
24
2
26
Pricing

Price Comparison

  • BESTGeo PeptidesUS
    10mg
    $34.99
    Price/mg
    $3.50/mg
  • Puratek PeptidesUS
    10mg
    $37.95
    $34.16
    Price/mg
    $3.80$3.42/mg
    View10% · PEPSTACKS10
  • Research Peptides UKUK
    5mg
    $18.99
    Price/mg
    $3.80/mg
  • Proto PeptideUS
    10mg
    $40.00
    Price/mg
    $4.00/mg
  • Step OneUS
    10mg
    $40.00
    Price/mg
    $4.00/mg

Top 5 of 59 offers from 66 vendors. Prices updated daily.

See all Ipamorelin prices
Mechanism

Tools

Mechanism

Related Peptides

Track Ipamorelin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer